FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Trial NCT06402331
Access comprehensive clinical trial information for NCT06402331 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Fusion Pharmaceuticals Inc. and is currently Recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fusion Pharmaceuticals Inc.
Timeline & Enrollment
Phase 2/3
Mar 05, 2024
Jan 23, 2031
Primary Outcome
Frequency, duration, and severity of treatment-emergent adverse events (TEAEs),Frequency and proportion of participants with PSA50 response
Summary
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I&T). The dose
 optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor
 activity of novel dosing regimens of FPI-2265 in participants with PSMA-positive mCRPC who
 have been previously treated with 177Lu-PSMA-617 or another 177Lu-PSMA radioligand therapy
 (RLT).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06402331
Non-Device Trial